{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:46:22Z","timestamp":1782776782196,"version":"3.54.5"},"reference-count":20,"publisher":"Oceanside Publications Inc.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold>Hereditary angioedema (HAE) is a rare disease that affects 1 in 60,000; however, despite being extremely rare, the severity of the disease can cause significant limitations to quality of life. In addition, attacks can be fatal and require urgent care.<jats:bold>Methods:<\/jats:bold>We searched PubMed and Google for Hereditary Angioedema and prophylaxis, short term prophylaxis, surgery, medical procedures, dental work, triggers.<jats:bold>Results:<\/jats:bold>The main triggers are estrogens, Angiotensin Converting Enzyme Inhibitors (ACI) inhibitors, trauma, dental work, stress, surgery, manipulation of the upper airway, and medical procedures. Prophylaxis is often used long term to prevent attacks; before known triggers, prophylaxis is referred to as short-term prophylaxis (STP). When to initiate STP, what to use, and what dose to use have not been adequately researched, but there is consensus that, whenever the upper airway is manipulated, STP is essential. In addition, consensus has been reached that an IV C1 inhibitor is the preferred STP agent, and it is my opinion that dosing at 20 units\/kg allows dosing for all ages and also allows average-size adults to receive &gt;1000 units because failures at 1000 units have been documented in the literature.<jats:bold>Conclusions:<\/jats:bold>This article focused on triggers and preprocedural STP and not on pre-event STP, which is often used before important life events; however, medications and dosing are the same for pre-event prophylaxis.<\/jats:p>","DOI":"10.2500\/aap.2020.41.200058","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T04:41:14Z","timestamp":1603860074000},"page":"S30-S34","source":"Crossref","is-referenced-by-count":36,"title":["Triggers and short-term prophylaxis in patients with hereditary angioedema"],"prefix":"10.2500","volume":"41","author":[{"given":"Timothy","family":"Craig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/all.13384","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema\u2014the 2017 revision and update","volume":"73","author":"Maurer","year":"2018","journal-title":"Allergy"},{"key":"B2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13223-019-0376-8","article-title":"The International\/Canadian Hereditary Angioedema Guideline","volume":"15","author":"Betschel","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B3","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/all.13001","article-title":"International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency","volume":"72","author":"Farkas","year":"2017","journal-title":"Allergy"},{"key":"B4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jaip.2013.07.002","article-title":"US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency","volume":"1","author":"Zuraw","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B5","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jaci.2011.11.025","article-title":"International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency","volume":"129","author":"Caballero","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2500\/ar.2015.6.0112","article-title":"Perioperative management for patients with hereditary angioedema","volume":"6","author":"Williams","year":"2015","journal-title":"Allergy Rhinol (Providence)"},{"key":"B7","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/all.12032","article-title":"Short-term prophylaxis in hereditary angioedema due to deficiency of the C1-inhibitor\u2014a long-term survey","volume":"67","author":"Farkas","year":"2012","journal-title":"Allergy"},{"key":"B8","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0278-2391(99)90280-X","article-title":"The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental procedures","volume":"57","author":"Farkas","year":"1999","journal-title":"J Oral Maxillofac Surg"},{"key":"B9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0091-6749(77)90080-X","article-title":"Tranexamic acid: preoperative prophylactic therapy for patients with hereditary angioneurotic edema","volume":"60","author":"Sheffer","year":"1977","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.tripleo.2011.02.034","article-title":"Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study","volume":"112","author":"Bork","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"B11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2500\/aap.2012.33.3585","article-title":"Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent hereditary angioedema attacks","volume":"33","author":"Grant","year":"2012","journal-title":"Allergy Asthma Proc"},{"key":"B12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jaci.2009.07.017","article-title":"Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks","volume":"124","author":"Craig","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1710-1492-10-17","article-title":"The prophylactic use of C1 inhibitor in hereditary angioedema patients undergoing invasive surgical procedures: a retrospective study","volume":"10","author":"Gavigan","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.anai.2016.10.006","article-title":"Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema: findings from an international patient registry","volume":"118","author":"Magerl","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jaip.2019.08.011","article-title":"Recombinant human C1 esterase inhibitor as short-term prophylaxis in patients with hereditary angioedema","volume":"8","author":"Valerieva","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1081-1206(10)60886-1","article-title":"Fresh frozen plasma for the treatment of hereditary angioedema","volume":"98","author":"Prematta","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0714.1991.tb00908.x","article-title":"Oral manifestations and dental management of patients with hereditary angioedema","volume":"20","author":"Atkinson","year":"1991","journal-title":"J Oral Pathol Med"},{"key":"B18","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.jaip.2019.01.054","article-title":"Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks","volume":"7","author":"Craig","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B19","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2217\/imt-2018-0197","article-title":"A review of kallikrein inhibitor lanadelumab in hereditary angioedema","volume":"11","author":"Hwang","year":"2019","journal-title":"Immunotherapy"},{"key":"B20","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.2217\/imt-2019-0128","article-title":"Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedema","volume":"11","author":"Hwang","year":"2019","journal-title":"Immunotherapy"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2020\/00000041\/a00106s1\/art00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T03:35:17Z","timestamp":1698291317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2020.41.200058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,1]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11,1]]}},"alternative-id":["1088-5412(20201101)41:6+L.30;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2020.41.200058","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,1]]}}}